Cargando…

Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders

Spherical nucleic acids (SNAs) are nanostructures consisting of nucleic acids in a spherical configuration, often around a nanoparticle core. SNAs are advantageous as gene-regulating agents compared to conventional gene therapy owing to their low toxicity, enhanced stability, uptake by virtually any...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmes, Thomas R., Paller, Amy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693734/
https://www.ncbi.nlm.nih.gov/pubmed/33147737
http://dx.doi.org/10.3390/ph13110360
_version_ 1783614813477273600
author Holmes, Thomas R.
Paller, Amy S.
author_facet Holmes, Thomas R.
Paller, Amy S.
author_sort Holmes, Thomas R.
collection PubMed
description Spherical nucleic acids (SNAs) are nanostructures consisting of nucleic acids in a spherical configuration, often around a nanoparticle core. SNAs are advantageous as gene-regulating agents compared to conventional gene therapy owing to their low toxicity, enhanced stability, uptake by virtually any cell, and ability to penetrate the epidermal barrier. In this review we: (i) describe the production, structure and properties of SNAs; (ii) detail the mechanism of SNA uptake in keratinocytes, regulated by scavenger receptors; and (iii) report how SNAs have been topically applied and intralesionally injected for skin disorders. Specialized SNAs called nanoflares can be topically applied for gene-based diagnosis (scar vs. normal tissue). Topical SNAs directed against TNFα and interleukin-17A receptor reversed psoriasis-like disease in mouse models and have been tested in Phase 1 human trials. Furthermore, SNAs targeting ganglioside GM3 synthase accelerate wound healing in diabetic mouse models. Most recently, SNAs targeting toll-like receptor 9 are being used in Phase 2 human trials via intratumoral injection to induce immune responses in Merkel cell and cutaneous squamous cell carcinoma. Overall, SNAs are a valuable tool in bench-top and clinical research, and their advantageous properties, including penetration into the epidermis after topical delivery, provide new opportunities for targeted therapies.
format Online
Article
Text
id pubmed-7693734
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76937342020-11-28 Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders Holmes, Thomas R. Paller, Amy S. Pharmaceuticals (Basel) Review Spherical nucleic acids (SNAs) are nanostructures consisting of nucleic acids in a spherical configuration, often around a nanoparticle core. SNAs are advantageous as gene-regulating agents compared to conventional gene therapy owing to their low toxicity, enhanced stability, uptake by virtually any cell, and ability to penetrate the epidermal barrier. In this review we: (i) describe the production, structure and properties of SNAs; (ii) detail the mechanism of SNA uptake in keratinocytes, regulated by scavenger receptors; and (iii) report how SNAs have been topically applied and intralesionally injected for skin disorders. Specialized SNAs called nanoflares can be topically applied for gene-based diagnosis (scar vs. normal tissue). Topical SNAs directed against TNFα and interleukin-17A receptor reversed psoriasis-like disease in mouse models and have been tested in Phase 1 human trials. Furthermore, SNAs targeting ganglioside GM3 synthase accelerate wound healing in diabetic mouse models. Most recently, SNAs targeting toll-like receptor 9 are being used in Phase 2 human trials via intratumoral injection to induce immune responses in Merkel cell and cutaneous squamous cell carcinoma. Overall, SNAs are a valuable tool in bench-top and clinical research, and their advantageous properties, including penetration into the epidermis after topical delivery, provide new opportunities for targeted therapies. MDPI 2020-11-02 /pmc/articles/PMC7693734/ /pubmed/33147737 http://dx.doi.org/10.3390/ph13110360 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Holmes, Thomas R.
Paller, Amy S.
Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders
title Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders
title_full Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders
title_fullStr Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders
title_full_unstemmed Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders
title_short Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders
title_sort gene regulation using spherical nucleic acids to treat skin disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693734/
https://www.ncbi.nlm.nih.gov/pubmed/33147737
http://dx.doi.org/10.3390/ph13110360
work_keys_str_mv AT holmesthomasr generegulationusingsphericalnucleicacidstotreatskindisorders
AT palleramys generegulationusingsphericalnucleicacidstotreatskindisorders